| 输血依赖型较低危组骨髓增生异常综合征的治疗进展 |
| |
| 引用本文： | 冯悦,罗兴春,朱玉,刘蓓.输血依赖型较低危组骨髓增生异常综合征的治疗进展[J].肿瘤防治研究,2021,48(4):409-413. |
| |
| 作者姓名： | 冯悦 罗兴春 朱玉 刘蓓 |
| |
| 作者单位： | 1. 730000 兰州，兰州大学第一临床医学院； 2. 730000 兰州，兰州大学第一医院血液科 |
| |
| 摘 要： | 目前输血依赖型较低危组骨髓增生异常综合征（LR-MDS）患者在促红细胞生成剂治疗无效或复发后的治疗选择有限。MDS的病理学和分子遗传学研究推进了MDS精准化治疗的发展，小分子抑制剂如转化生长因子β抑制剂、端粒酶抑制剂、低氧诱导因子脯氨酰羟化酶抑制剂等为患者提供了新的治疗方案。本文综述了输血依赖型LR-MDS患者的治疗，并着重讨论了新的靶向药物的最新临床研究及进展。
|
| 关 键 词： | 输血依赖 较低危组骨髓增生异常综合征 小分子抑制剂 |
| 收稿时间： | 2020-09-04 |
Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes |
| |
| FENG Yue,LUO Xingchun,ZHU Yu,LIU Bei.Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes[J].Cancer Research on Prevention and Treatment,2021,48(4):409-413. |
| |
| Authors: | FENG Yue LUO Xingchun ZHU Yu LIU Bei |
| |
| Affiliation: | 1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China; 2. Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, China |
| |
| Abstract: | At present,the patients with transfusion-dependent lower-risk myelodysplastic syndromes(MDS)have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed.With more understanding of the pathological and molecular genetics characteristics of MDS,the development of precise medical treatment of MDS has been promoted.Small-molecule inhibitors,such as transforming growth factorβinhibiter,telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor,provide novel therapeutic strategies for patients.This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents. |
| |
| Keywords: | Transfusion-dependency Lower-risk myelodysplastic syndromes Small-molecule inhibitors |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
|
点击此处可从《肿瘤防治研究》下载全文 |
